Herantis Pharma to Host a Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout
Herantis Pharma Plc (“Herantis” or “Company”) will be hosting a webinar to share more details on CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months .Herantis Pharma PlcCompany release September 4, 2020 at 9:00 AM Eastern European Summer Time Event Details: CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months Date and Time: September 15, 2020 at 15:00 – 16:00 CET